Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe sold 14,362 shares of Adaptimmune Therapeutics stock in a transaction dated Tuesday, January 11th. The stock was sold at an average price of $3.56, for a total value of $51,128.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Adrian Rawcliffe also recently made the following trade(s):
- On Tuesday, January 4th, Adrian Rawcliffe sold 5,532 shares of Adaptimmune Therapeutics stock. The stock was sold at an average price of $4.06, for a total value of $22,459.92.
Shares of Adaptimmune Therapeutics stock opened at $3.30 on Friday. Adaptimmune Therapeutics plc has a 52-week low of $3.16 and a 52-week high of $7.34. The stock has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $4.45.
Institutional investors have recently made changes to their positions in the company. PFM Health Sciences LP lifted its holdings in shares of Adaptimmune Therapeutics by 45.0% during the 2nd quarter. PFM Health Sciences LP now owns 3,627,900 shares of the biotechnology company’s stock valued at $15,455,000 after buying an additional 1,126,597 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in shares of Adaptimmune Therapeutics by 9.6% during the 3rd quarter. Baillie Gifford & Co. now owns 12,824,980 shares of the biotechnology company’s stock valued at $66,306,000 after buying an additional 1,128,061 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Adaptimmune Therapeutics during the 2nd quarter valued at about $546,000. Vigilare Wealth Management lifted its holdings in shares of Adaptimmune Therapeutics by 84.2% during the 3rd quarter. Vigilare Wealth Management now owns 99,950 shares of the biotechnology company’s stock valued at $517,000 after buying an additional 45,700 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Adaptimmune Therapeutics by 5,908.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 15,382 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 15,126 shares during the last quarter. Institutional investors and hedge funds own 71.38% of the company’s stock.
A number of research firms recently issued reports on ADAP. Zacks Investment Research lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 10th. SVB Leerink reissued a “hold” rating and issued a $7.00 price target on shares of Adaptimmune Therapeutics in a research note on Tuesday, November 9th. Finally, Wells Fargo & Company lifted their target price on Adaptimmune Therapeutics from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Wednesday, September 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.75.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.